Adipotide (FTPP) is a purely experimental, targeted pro-apoptotic peptide studied only in preclinical models. It is not approved and has no established human clinical use. This page describes hypothesized and investigational ideas, not benefits established in people.
Overview
Adipotide is a fat-targeting proapoptotic peptide designed to reduce white adipose tissue by acting on its blood supply. Because of this mechanism, research interest has centred on:
- A vascular-targeting approach to reducing fat mass rather than an appetite or metabolic one.
- Whether disrupting the blood supply of fat tissue can translate into weight loss.
- What such a mechanism would require to be safe, which remains a central open question.
These are the ideas researchers study; they are not a promise of any cosmetic, athletic, or clinical result in humans.
Targeted fat reduction concept
The conceptual appeal of adipotide is selectivity: a peptide sequence intended to home to receptors associated with the vasculature of white fat, paired with a pro-apoptotic element intended to trigger cell death in those vessels. The hypothesis is that removing the blood supply could shrink fat depots. This is a mechanism-driven idea, not a demonstrated human outcome.
Preclinical weight-loss signals
The most cited research involved obese non-human primates, where treatment was associated with reductions in body weight. These preclinical signals generated scientific interest, but they came alongside safety concerns and have not been reproduced as an established effect in controlled human trials.
How adipotide differs from metabolic peptides
Adipotide sits apart from many peptides discussed for body composition:
- Mechanism — it targets adipose vasculature rather than appetite, GH, or lipid pathways.
- Action — it is pro-apoptotic, intended to trigger cell death, rather than modulating a signalling pathway.
- Stage — it is purely preclinical, with no human clinical use.
Evidence and caveats
Preclinical weight-loss signals are not the same as proven, safe benefit in people. Key caveats:
- It is not approved for human use anywhere.
- Animal studies raised renal-toxicity concerns.
- There is no established human efficacy or safety data.
- Marketing framing it as a fat-loss agent overstates the evidence.